Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

2012 NBJ Summit

Summary

Speakers

Joanne M. Gray

Thomas C. Meriam

John R. LeClaire

Related Content

New Momentum for a Time-Limited Conditional Approval Pathway for Rare Disease Drugs

A Look Ahead in Life Sciences: What We Are Tracking in the Fourth Quarter of 2024 and Beyond

Common FDA Bioresearch Monitoring (BIMO) Violations: Updates from FY 2023 to Now

A Look Ahead in Life Sciences: What We Are Tracking in the Third Quarter of 2024 and Beyond

Form SHL: What You Need to Know

Designating a Platform Technology: FDA’s Long-Awaited Draft Guidance

FDA Finalizes Rule and Sets Course to Phase In Oversight of Laboratory Developed Tests

A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Best Lawyers Best Law Firms 2025 Names Goodwin Biotechnology and Life Sciences Law Firm of the Year for the Eighth Time and Recognizes 55 Practice Areas

Preparing for the US Biosecure Act - What Does It Mean for the Pharma Industry? (Outsourcing Pharma)

Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards

Test-Makers See Way Out Of FDA Rule With Chevron Reversal (Law360)

Rapport Therapeutics Completes $174.4 Millon Initial Public Offering and Concurrent Private Placement

Chambers USA 2024 Recognizes Goodwin Practices and Lawyers for Exceptional Client Service

Akili Interactive to Be Acquired by Virtual Therapeutics

Food & Healthy Living

Life Sciences Regulatory & Compliance